DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection

Information source: Hospices Civils de Lyon
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Influenza A Infection

Intervention: oseltamivir + zanamivir (Drug); oseltamivir+ amantadine (Drug); oseltamivir (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Hospices Civils de Lyon

Official(s) and/or principal investigator(s):
BRUNO LINA, MD,PhD, Principal Investigator, Affiliation: Hospices Civils de Lyon


Neuraminidase inhibitors (NAI) are effective anti-influenza antiviral treatment. During their use in experimentally infected patients, it has been shown that the viral load detected in the nasal fluid is decreasing significantly faster than in non treated patients. During clinical practice, the emergence of NAI-resistant strains has been observed. These strains remain rare, but their emergence seemed to be related to the mis-use of the NAI products (insufficient duration or dosage). This observation as well as the detection of NAI-resistant viruses in the community raises concerns about putative emergence of resistant clones in the specific context of a pandemic, when the use of NAI will be very large in the aim of reducing transmission, and subsequently the impact of the emerging virus. In this context, it is important to determine the putative interest of alternative strategies. Although zanamivir and oseltamivir are both issued from the same class , this combination may lead to a more rapid viral clearance in the infected cases, and to a reduction in the emergence of resistant sub-clones, and alternatively, might lead to a competitive inhibition. The evaluation of these combinations needs to be conducted in vivo. Among available anti influenza antivirals, M2 blockers have been previously used. Although their efficacy against A H5N1 remains to be ascertained, their use in combination with NAI should also be evaluated in the context of a preparation for a possible pandemic and determination of the stockpile. Therefore, the evaluation of combination therapies in the treatment of a virologically suspected influenza will be investigated in primary care during the winter season 2008-2009.

Clinical Details

Official title: Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

describe the antiviral efficacy in the 3 arms in the treatment of seasonal influenza infection as assessed by negative viral detection in nose swabs at the fifth swab [H48±3]

Describe the antiviral efficacy in 3 arms in the treatment of seasonal influenza infection as assessed by negativity of RT-PCR for viral RNA in nose and throat swabs at the 5th swab [H48±3] and at the 7th swab [H84±3].

Secondary outcome:

Describe the antiviral efficacy in combination therapy arms (1,2) and in monotherapy arm (3) in the treatment of seasonal influenza infection as assessed by time to sustained negativity of RT-PCR for viral RNA or viral culture in any sample.

Assess viral replication dynamics (duration and level of viral replication) in the respiratory tract in the combination and standard-dose cohorts.

Assess the frequency, genetic basis, and duration of antiviral resistance to each arm during and after therapy

Describe the time to alleviation of illness in the 3 arms defined as the time from the beginning of the study treatment to the time that 7 typical key symptoms of natural influenza had reduced to absent or mi

Describe the tolerability of combination and in standard-dose arms as assessed by clinical adverse events that are possibly or probably related to each single agent (Incidence and duration)

Detailed description: Study Schedule:

- Patient's follow up: 7 days with 10 visits V1, V2, V3, V4, V5 every 12 hours V6, V7,

V8, V9, V10 every 24 hours

- V1: conducted by the GP rapid test diagnostic for influenza A, urine pregnancy test for

women, inclusion /randomisation, nasal sample, initiation of treatment.

- V2 to V9: conducted by a nurse at the patient's home; nasal sample, symptoms scoring,

safety assessment (side effects)

- V 10: conducted by GP; medical evaluation (follow up evaluation)


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Influenza season declared

- Subjects aged>18 years and < 65 years presenting within 36h documented of onset

influenza illness

- Who have fever >38°C

- Who present at least one of the following respiratory symptoms (cough, sore throat,

nasal symptoms), and one of the following constitutional symptoms (headache, myalgia, sweats and or chills or fatigue)

- Positive rapid diagnostic test for influenza A

- Who have giving written informed consent prior to enrollment

- Patient examined before the inclusion

- Primary care follow up

Exclusion Criteria:

- Influenza Vaccination in the 12 months prior the beginning of the study

- Asthma, Chronic bronchitis

- Woman with a positive urine pregnancy test

- Active breast feeding

- Woman without contraception

- Clearance of creatinine< 30 ml/min Chronic renal disease

- History of depression, psychiatric disorders, epilepsy

- Patients receiving cortocosteroids, immunosuppressants or antipsychotic antiemetic


- Known oseltamivir or zanamivir hypersensibility

- Non member of the social security or CMU

Locations and Contacts

Hospices civils de Lyon, Lyon, France
Additional Information

Starting date: January 2009
Last updated: September 29, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017